CN109652559A - A kind of mankind RhD blood group gene parting detection primer group and application - Google Patents
A kind of mankind RhD blood group gene parting detection primer group and application Download PDFInfo
- Publication number
- CN109652559A CN109652559A CN201811439472.1A CN201811439472A CN109652559A CN 109652559 A CN109652559 A CN 109652559A CN 201811439472 A CN201811439472 A CN 201811439472A CN 109652559 A CN109652559 A CN 109652559A
- Authority
- CN
- China
- Prior art keywords
- primer
- dna
- artificial sequence
- blood group
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of mankind RhD blood group gene parting detection primer groups, including primer 16 shown in SEQ ID No.1-32 is to primer；The present invention is based on polymerase chain reaction (fluorescent PCR) reaction principle, first base and allele-specific base complementrity of the end primer 3', specific primer is to only expanding matched allele；Human genome sequencing disclosed in the blood group antigens gene mutation database (dbRBC) in DNA sequence data library (Genbank) that design of primers is established according to National Center for Biotechnology Information (NCBI), selects suitable specific mutations point design primer；PCR, which mixes dye method, indicates the effect of DNA cloning by mixing the amplified production of DNA with fluorescent dye.Melting curve analysis is carried out after amplification.It whether can confirm that purpose product by specific amplification by melting curve analysis, allele judged with this.
Description
Technical field
The present invention relates to gene diagnosis product technique field, specially a kind of mankind RhD blood group gene parting detection primer
Group and application.
Background technique
Rh blood group is the most complicated in human erythrocyte's blood group system, the most system of polymorphism, and is caused clinical defeated
The main erythrocyte blood type of blood reaction and serious neonatal hemolytic disease.Have now been found that more than 50 kinds of Rh blood group antigens, wherein RhD is anti-
Original has very strong immunogenicity, is to be encoded to generate by RhD gene, is the emphasis of blood group research.The common parting of Chinese
There are the detection of the allele of Weak RhD 15 and DEL RhD1227A and RhD exons 1-7,9-10 and RhC, Rhc, RhE,
Rhe tetra- common Rh blood group antigens gene pleiomorphisms, but lack in the prior art to the detection of mankind's RhD blood group gene parting
The assay kit of comprehensive globality.
Summary of the invention
The technical problem to be solved by the present invention is to overcome lack in the prior art to the detection of mankind's RhD blood group gene parting
The defect of the assay kit of comprehensive globality provides a kind of mankind RhD blood group gene parting detection primer group and application.
In order to solve the above-mentioned technical problems, the present invention provides the following technical solutions:
A kind of mankind RhD blood group gene parting detection primer group, which is characterized in that including contained by SEQ ID No.1-30
15 pairs of primers.
Above-mentioned primer pair can be applied in the product of preparation detection mankind RhD blood group gene parting detection.
A kind of kit of detection mankind RhD blood group gene parting detection, including the SEQ ID described in claim 1
Primer, dNTP-Buffer, cresol red sodium salt and the SYBR Green I of No.1-30 sequence.
Further, the detection of every person-portion includes 15 detection holes, removes in every hole and places a pair of alleles primer pair, also
Including internal reference Quality Control primer, sequence is as shown in SEQ ID No.31 and SEQ ID No.32.
Mentioned reagent box is used for qualitative detection human erythrocyte blood group antigens Genotyping.Include:
D-Exon1、D-Exon2、D-Exon3、D-Exon4、D-Exon5、D-Exon6、 D-Exon7、D-Exon9、D-
Exon10, weakD15, Del1227, RhC, Rhc, RhE and Rhe；
Wherein, detect blood group D-Exon1 allele primer pair E1ZH and E1F, sequence be respectively SEQ ID No.1 and
Shown in 2；Allele the primer pair E2ZH and E2F of blood group D-Exon2 are detected, sequence is respectively shown in SEQ ID No.3 and 4；
Allele the primer pair E3ZH and E3F of blood group D-Exon3 are detected, sequence is respectively shown in SEQ ID No.5 and 6；Detect blood
Allele the primer pair D-Exon4 and E4F of type D-Exon4, sequence is respectively shown in SEQ ID No.7 and 8；Detect blood group D-
Allele the primer pair E5ZH and E5F of Exon5, sequence is respectively shown in SEQ ID No.9 and 10；Detect blood group D-Exon6
Allele primer pair E6ZH and E6F, sequence is respectively shown in SEQ ID No.11 and 12；Detection blood group D-Exon7 etc.
For position gene primer to E7ZH and E7F, sequence is respectively shown in SEQ ID No.13 and 14；Detect the equipotential base of blood group D-Exon9
Because of primer pair E9ZH and E9F, sequence is respectively shown in SEQ ID No.15 and 16；The allele of detection blood group D-Exon10 draws
For object to E10ZH and E10F, sequence is respectively shown in SEQ ID No.17 and 18；
Detect blood group weakD15 allele primer pair 845ZH and 845F, sequence be respectively SEQ ID No.19 and
Shown in 20；
Detect blood group Del1227 allele primer pair 1227ZH and 1227F, sequence be respectively SEQ ID No.21 and
Shown in 22；
Allele the primer pair RhCF and RhCR of blood group RhC are detected, sequence is respectively shown in SEQ ID No.23 and 24；
Allele the primer pair RhcF and RhcR of blood group Rhc are detected, sequence is respectively shown in SEQ ID No.25 and 26；
Allele primer pair RhEF and the RhER sequence for detecting blood group RhE is respectively shown in SEQ ID No.27 and 28；
Allele the primer pair RheF and RheR of blood group Rhe are detected, sequence is respectively shown in SEQ ID No.29 and 30.
This method be based on polymerase chain reaction (fluorescent PCR) reaction principle, first base of the end primer 3' with etc.
Position gene specific base complementrity, specific primer is to only expanding matched allele；Design of primers is according to the U.S.
The blood group antigens gene mutation number in DNA sequence data library (Genbank) that National Biotechnology Information Center (NCBI) is established
According to human genome sequencing disclosed in library (dbRBC), suitable specific mutations point design primer is selected；PCR mix dye method with
Fluorescent dye indicates the effect of DNA cloning by mixing the amplified production of DNA.Melting curve analysis is carried out after amplification.It is logical
Whether cross melting curve analysis can confirm that purpose product by specific amplification, judge allele with this.
Detailed description of the invention
Attached drawing is used to provide further understanding of the present invention, and constitutes part of specification, with reality of the invention
It applies example to be used to explain the present invention together, not be construed as limiting the invention.In the accompanying drawings:
Positive findings example when Fig. 1 is kit of the present invention detection；
Negative findings example when Fig. 2 is kit of the present invention detection；
Null result example when Fig. 3 is kit of the present invention detection.
Specific embodiment
Hereinafter, preferred embodiments of the present invention will be described, it should be understood that preferred embodiment described herein is only used
In the description and interpretation present invention, it is not intended to limit the present invention.
Embodiment
A kind of kit detecting mankind RhD blood group gene parting, primer including SEQ ID No.1-30 sequence,
DNTP-Buffer, cresol red sodium salt and SYBR Green I.The detection of every person-portion includes 15 detection holes, removes in every hole and places one
It further include internal reference Quality Control primer, sequence is as shown in SEQ ID No.31 and SEQ ID No.32 to equipotential gene primer pair.
Condition of storage and validity period
All components of kit are saved at -18 DEG C or less, and validity period is 6 months.
Sample requirement:
1. sample needed for kit is whole blood, whole blood DNA extraction need to be carried out, and need to measure its DNA sample concentration.
2. extract DNA in whole blood, the whole blood sample of unusable anticoagulant heparin, it is recommended to use EDTA anti-coagulants.
3.DNA concentration of specimens should meet 40~70ng/ μ l, and purity A260/A280 value is 1.6~2.0.
4. -18 DEG C of DNA sample suggestion of extraction or less storage is completed not exceed 1 year.
The method of inspection
1, PCR working solution is prepared and (is carried out in preparation of reagents area)
It generally according to following table proportional arrangement 1ml, then is dispensed, is stored, DNA is added before use.
Oscillation mixes the several seconds, and 800rpm is centrifuged the several seconds.Other person-portions are prepared according to the above ratio.
2, sample-adding (being carried out in sample process area)
1, PCR working solution 160ul is taken to mix with sample DNA 16ul (concentration: 40~70ng/ul), whirlpool mixes work
Liquid-DNA mixed liquor 800rpm brief centrifugation 5~10 seconds, gathers tube wall residual liquid in tube bottom.
2, reacting hole (every 15 hole of person-portion) needed for shearing, every hole sample-adding 10ul state mixed liquor.
3, sealer or every hole are separately added into 15~20 μ l paraffin oils again, it is proposed that 96 orifice-plate types are centrifuged 7500rpm 1 minute.
3, PCR amplification (carries out) (real-time fluorescence quantitative PCR instrument wins day FQD-96A) in amplification region
Procedure selection SYBER GREEN I (is free of ROX)
Reaction volume setting: 10 μ L
Program setting: amplification curve acquisition
Program setting: 96 DEG C of 3min 1 circulations；96 DEG C recycle for 20 seconds, 68 DEG C 1min5；96 DEG C 20 seconds, 66 DEG C 50 seconds,
72 DEG C of 45 seconds 10 circulations；96 DEG C 20 seconds, 63 DEG C 50 seconds, 72 DEG C 45 seconds 15 circulation；72 DEG C of 2min 1 circulations.
Melting curve acquisition: 0.4 DEG C of heating per second, 1 fluorescent value of every 0.5 DEG C of acquisition, 60-95 DEG C of temperature collection range.
Quality control
There are melting peakss in corresponding temperature section in internal control primer, Quality Control means of the internal reference melting peakss as Successful amplification,
Negative hole should be always visible；The internal reference melting peakss in positive hole may be very weak or be not present, this is because specific primer
The result of the reaction raw materials such as Taq enzyme is competed in amplification procedure with internal control primer.
The analysis of inspection result
Initial data is opened with real-time fluorescence quantitative PCR genuine software, is found out using positive, negative Tm judgment value range
Positive hole.
Hole location, Genotyping, internal reference Tm and the positive Tm table of comparisons
Male/female judgment value
1. positive: when using intellectual analysis software, when there is the Tm of positive cutoff value (may have feminine gender simultaneously in the hole
Judgment value), then it is determined as the positive.When taking manual analysis, when there is the Tm of positive cutoff value range (may have simultaneously in the hole
Negative judgment value), and wave crest fluorescence derivative value be not less than 50 when, be determined as the positive.
2. negative: when there is the Tm of negative judgment value (internal reference) to be determined as when wave crest fluorescence derivative value is not less than 50 in the hole
It is negative.
In Fig. 1, dotted line table internal reference melting peakss, solid line table positive melting peakss；Positive findings: must be in corresponding positive temperature
There are melting peakss in section and peak is higher than derivative fluorescent value (Y axis) 50 with top for the positive.
In positive melting peakss have higher derivative fluorescent value that internal reference melting peakss may be made even to disappear lower than 50, are still considered as
Ginseng is effective, result is the positive
Dotted line table internal reference melting peakss in Fig. 2；Negative findings: internal reference melting peakss must melt in corresponding temperature section
Peak, peak are higher than 60 or more and 82 DEG C of derivative fluorescent value (Y-axis) or more section and derivative fluorescent value (Y-axis) do not occur higher than 50
Complete photoluminescence peak side be feminine gender.
The position Fig. 3 null result；There are not obvious melting peakss in the positive temperature range of specific interior participation.
Such situation need to re-operate experiment, Confirmation reagent state and DNA concentration quality and maintain and require section.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features.
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in of the invention
Within protection scope.
Sequence table
<110>Jiangsu Zhong Jiwantai biological medicine Co., Ltd
<120>a kind of mankind RhD blood group gene parting detection primer group and application
<130> D201810262
<141> 2018-11-29
<160> 32
<170> SIPOSequenceListing 1.0
<210> 1
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
cctccataga gaggccagca caat 24
<210> 2
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
cagtgcccct ggagaaccac a 21
<210> 3
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
ctttactgag tgtccatgtg cg 22
<210> 4
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
gctggattcc ttgtgataca gg 22
<210> 5
<211> 25
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
ctagtcggtg ctgatctcag tggac 25
<210> 6
<211> 26
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
ttactgatga ccatcctcag gttgcg 26
<210> 7
<211> 25
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 7
ctgctctgaa ctttctccaa ggaca 25
<210> 8
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 8
acttcagaca cccaggggaa cct 23
<210> 9
<211> 27
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 9
cgatgttctg gccaagtttc aactcga 27
<210> 10
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 10
cctgctcacc ttgctgatct tcct 24
<210> 11
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 11
acagtagtga gctggcccat ct 22
<210> 12
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 12
gcccaataag agaatgcgcc ac 22
<210> 13
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 13
ctagctccat catgggctac aag 23
<210> 14
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 14
cgacctgctc tgtgtttgtg gac 23
<210> 15
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 15
cggtccagga atgacagggc ac 22
<210> 16
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 16
cgttctgtca cccgcatgtc ac 22
<210> 17
<211> 26
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 17
acctcatttg gctgttggat tttatc 26
<210> 18
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 18
acagtgcctg cgcgaacatt ac 22
<210> 19
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 19
ccagtagtga gctggcccat ct 22
<210> 20
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 20
cggatcaggt gacacgaggc acta 24
<210> 21
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 21
gaatgaccaa gttttctgga agc 23
<210> 22
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 22
cgttctgtca cccgcatgtc acga 24
<210> 23
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 23
agtgcttcca gtgttagggc ac 22
<210> 24
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 24
ccttccgtgt taactccata gat 23
<210> 25
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 25
gtgatgacca ccttcccagg a 21
<210> 26
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 26
cctctcccca ccgagcagta g 21
<210> 27
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 27
cactgtgacc acccagcatt ctat 24
<210> 28
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 28
attctggcca agtgtcaact ctcg 24
<210> 29
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 29
ttcaggtggt ggaggttgcc t 21
<210> 30
<211> 24
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 30
cagattggac ttctcagcag agat 24
<210> 31
<211> 27
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 31
cacgtctgcc catcaccacc tattaga 27
<210> 32
<211> 29
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 32
accattaccc agagccctat cgttctcac 29
Claims (4)
1. a kind of mankind RhD blood group gene parting detection primer group, which is characterized in that including 15 contained by SEQ ID No.1-30
To primer.
2. application of the primer pair described in claim 1 in the product of preparation detection mankind RhD blood group gene parting detection.
3. a kind of kit of detection mankind RhD blood group gene parting detection, which is characterized in that including described in claim 1
Primer, dNTP-Buffer, cresol red sodium salt and the SYBR Green of SEQ ID No.1-30 sequence.Ⅰ
4. kit as claimed in claim 3, which is characterized in that the detection of every person-portion includes 15 detection holes, is removed in every hole
A pair of alleles primer pair is placed, further includes internal reference Quality Control primer, sequence such as SEQ ID No.31 and SEQ ID No.32
It is shown.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811439472.1A CN109652559A (en) | 2018-11-29 | 2018-11-29 | A kind of mankind RhD blood group gene parting detection primer group and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811439472.1A CN109652559A (en) | 2018-11-29 | 2018-11-29 | A kind of mankind RhD blood group gene parting detection primer group and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109652559A true CN109652559A (en) | 2019-04-19 |
Family
ID=66111866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811439472.1A Pending CN109652559A (en) | 2018-11-29 | 2018-11-29 | A kind of mankind RhD blood group gene parting detection primer group and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109652559A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111154766A (en) * | 2020-01-16 | 2020-05-15 | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | RHD-S68R mutant and detection method thereof |
| CN111218453A (en) * | 2020-03-10 | 2020-06-02 | 无锡市第五人民医院 | RhD blood type antigen RHD-G353A mutant and detection |
| CN111363794A (en) * | 2020-04-20 | 2020-07-03 | 江苏省血液中心 | Detection primer group for red blood cell RHD c.1227G > A genotyping and analysis method |
| CN116042854A (en) * | 2022-12-27 | 2023-05-02 | 江苏中济万泰生物医药有限公司 | Diego blood group genotyping primer set, kit and detection method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004089057A (en) * | 2002-08-30 | 2004-03-25 | Nippon Sekijiyuujishiya | Method for judging rh negative |
| CN1552918A (en) * | 2003-12-15 | 2004-12-08 | 深圳市血液中心 | Primer, reagent box and sizing method for Chinese the Han nationality crowd differential RHD gene sizing |
| CN101065499A (en) * | 2004-09-22 | 2007-10-31 | 英国西英格兰大学，布里斯托尔 | RHD and ABO genotyping by multiplex PCR |
| CN101597642A (en) * | 2009-04-23 | 2009-12-09 | 陕西省血液中心 | A kind of multiple PCR method and test kit that detects human RhD blood type and gene type |
| CN106967808A (en) * | 2017-04-11 | 2017-07-21 | 青岛市中心血站（青岛市公民义务献血办公室青岛市输血医学研究所） | A kind of primer sets and its application for being used to detect RhD negative blood groups |
| WO2017194973A1 (en) * | 2016-05-13 | 2017-11-16 | University Of Plymouth | Method for bood group genotyping |
| CN108103204A (en) * | 2017-12-15 | 2018-06-01 | 东莞博奥木华基因科技有限公司 | The Rh blood grouping method and devices being sequenced based on multiplex PCR and two generations |
-
2018
- 2018-11-29 CN CN201811439472.1A patent/CN109652559A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004089057A (en) * | 2002-08-30 | 2004-03-25 | Nippon Sekijiyuujishiya | Method for judging rh negative |
| CN1552918A (en) * | 2003-12-15 | 2004-12-08 | 深圳市血液中心 | Primer, reagent box and sizing method for Chinese the Han nationality crowd differential RHD gene sizing |
| CN101065499A (en) * | 2004-09-22 | 2007-10-31 | 英国西英格兰大学，布里斯托尔 | RHD and ABO genotyping by multiplex PCR |
| CN101597642A (en) * | 2009-04-23 | 2009-12-09 | 陕西省血液中心 | A kind of multiple PCR method and test kit that detects human RhD blood type and gene type |
| WO2017194973A1 (en) * | 2016-05-13 | 2017-11-16 | University Of Plymouth | Method for bood group genotyping |
| CN106967808A (en) * | 2017-04-11 | 2017-07-21 | 青岛市中心血站（青岛市公民义务献血办公室青岛市输血医学研究所） | A kind of primer sets and its application for being used to detect RhD negative blood groups |
| CN108103204A (en) * | 2017-12-15 | 2018-06-01 | 东莞博奥木华基因科技有限公司 | The Rh blood grouping method and devices being sequenced based on multiplex PCR and two generations |
Non-Patent Citations (7)
| Title |
|---|
| C.GASSNER等: ""RHD/CE typing by polymerase chain reaction using sequence-specific primers"", 《TRANSFUSION》 * |
| JUNG-CHIN CHEN等: ""RHD 1227A Is an Important Genetic Marker for RhDel Individuals"", 《AM J CLIN PATHOL.》 * |
| 任本春: ""福建地区人群弱D表现型分子机制研究"", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 王霓 等: ""熔解曲线分析法用于RHD 1227G＞A 基因分型的实验研究"", 《中国输血杂志》 * |
| 郑全: ""Rh血型基因定型方法的实验研究"", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 陆松松 等: ""两步法分析RhD阴性及D变异体分子机制(附1例新等位基因的发现)"", 《中国输血杂志》 * |
| 陆松松: ""RHD基因检测试剂盒的开发与应用"", 《万方平台》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111154766A (en) * | 2020-01-16 | 2020-05-15 | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | RHD-S68R mutant and detection method thereof |
| CN111154766B (en) * | 2020-01-16 | 2023-04-25 | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | RHD-S68R mutant and detection method thereof |
| CN111218453A (en) * | 2020-03-10 | 2020-06-02 | 无锡市第五人民医院 | RhD blood type antigen RHD-G353A mutant and detection |
| CN111218453B (en) * | 2020-03-10 | 2020-12-18 | 无锡市第五人民医院 | RhD blood type antigen RHD-G353A mutant and detection |
| CN111363794A (en) * | 2020-04-20 | 2020-07-03 | 江苏省血液中心 | Detection primer group for red blood cell RHD c.1227G > A genotyping and analysis method |
| CN116042854A (en) * | 2022-12-27 | 2023-05-02 | 江苏中济万泰生物医药有限公司 | Diego blood group genotyping primer set, kit and detection method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109652559A (en) | A kind of mankind RhD blood group gene parting detection primer group and application | |
| EP2971123B1 (en) | Nucleic acid amplification | |
| US20240018587A1 (en) | Methods to detect a silent carrier genotype | |
| CN109486963A (en) | A kind of mankind KIR Genotyping detection primer group and application | |
| EP2038426A2 (en) | Methods and compositions for the amplification, detection and quantification of nucleic acid from a sample | |
| CN112239787A (en) | Primer, probe, kit and device for detecting human IDH1 gene mutation | |
| CN111850117A (en) | Primer, probe, kit and device for detecting mutation of human TERT promoter | |
| CN104120178A (en) | Method for detection of ESR1 gene mutations based on fluorescent PCR technology | |
| EP3325152A1 (en) | Automated sample to ngs library preparation | |
| EP3564370A1 (en) | Nucleic acid amplification | |
| CN106967810B (en) | Method and kit for detecting FGFR3 gene mutation to diagnose bladder cancer | |
| CN111394434B (en) | CHO host cell DNA residue detection kit adopting TaqMan probe method and application thereof | |
| CN109136354A (en) | A kind of human erythrocyte's rare blood type genotyping primer group and application | |
| CN103103259A (en) | Method, kit and primers for determining whether two predetermined loci of nucleic acid sample mutate or not | |
| CN109628559B (en) | Method and kit for detecting Y chromosome copy number variation | |
| CN102282176A (en) | Non-invasive fetal rhd genotyping from maternal whole blood | |
| CN109295192A (en) | A kind of composition, kit, sample treatment and application detecting people MDR1 gene pleiomorphism | |
| CN205347395U (en) | Leber heredity optic neuropathy gene detect reagent box | |
| CN108504731B (en) | Method for diagnosing lipid metabolism-related diseases or Alzheimer's disease markers | |
| CN109385487B (en) | Recombinase-mediated amplification isothermal detection method and kit for American ginseng as Chinese medicinal herb | |
| CN105969842A (en) | Glu504lys detection genotyping kit based on AllGlo probe and genotyping method thereof | |
| CN111471751A (en) | Method capable of quantitatively detecting human DNA in animal blood or tissue | |
| EP2495335B1 (en) | Probe for detecting polymorphism in egfr genes, and usage therefor | |
| CN107287304A (en) | A kind of application for the Primer composition that gene pleiomorphism is detected based on HRM | |
| CN103421883A (en) | RET fusion gene screening method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |